WallStSmart

Merck & Company Inc (MRK)vsP3 Health Partners Inc (PIII)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 4367% more annual revenue ($65.77B vs $1.47B). MRK leads profitability with a 13.6% profit margin vs -8.6%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

PIII

Avoid

34

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: -1.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$128.66

$47.70 premium

UndervaluedFair: $80.96Overvalued

Intrinsic value data unavailable for PIII.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

PIII1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.4310/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PIII4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
3.5%4/10

3.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
2.1%3/10

Operating margin of 2.1%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : PIII

The strongest argument for PIII centers on Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : PIII

The primary concerns for PIII are Revenue Growth, EPS Growth, Operating Margin.

Key Dynamics to Monitor

MRK profiles as a value stock while PIII is a turnaround play — different risk/reward profiles.

PIII carries more volatility with a beta of 1.60 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 34/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

P3 Health Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

P3 Health Partners Inc (PIII) is a pioneering healthcare organization focused on improving care quality and reducing costs through innovative, data-driven strategies. The company utilizes telehealth technologies and advanced analytics to provide customized healthcare solutions, particularly to underserved communities, and operates a comprehensive network of primary care providers and specialists. As a leader in value-based care models, P3 partners with community organizations to address the increasing demand for efficient healthcare services. With its strong dedication to delivering high-quality, cost-effective care, PIII is strategically positioned to succeed in the rapidly changing healthcare landscape.

Want to dig deeper into these stocks?